A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282

Addpharma

Status and phase: Not yet enrolling; Phase 3

Conditions: Primary Hypercholesterolemia

Treatments: Drug: AD-2281; Drug: Placebo of AD-2282; Drug: AD-2282

Study type: Interventional

Funder types: Industry

Identifiers

NCT06747936

AD-228P3

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia

Enrollment: 110 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent
• Patients with Primary Hypercholesterolemia
• Other inclusions applied

Exclusion criteria

• Patients with Secondary Hypercholesterolemia
• Other exclusions applied

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

110 participants in 2 patient groups

AD-2281 + AD-2282

Experimental group

Treatment:

Drug: AD-2282

Drug: AD-2281

AD-2281 + Placebo of AD-2282

Active Comparator group

Treatment:

Drug: Placebo of AD-2282

Drug: AD-2281